Atezolizumab is now FDA approved in the first-line setting in combination with carboplatin, paclitaxel, and bevacizumab for patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor mutations. Here, EGFR is linked to non-small cell lung carcinoma.